Expert perspective outlines key hurdles in translating microphysiological systems into drug development, highlighting pathways to replace animal testing.
Microphysiological Systems (MPS) feature cells, often cultured in 3D, within a microfluidic circuit aiming to mimic the circulation and cross-talk between organs found in the human body. These platforms have proven useful in different contexts, ranging from basic biology research to disease modelling and drug development - all with the underlying aim of reducing our reliance on animal experiments. In addition to dedicating a “cross-journal collection [https://www.nature.com/collections/fgjeddegjc]” to this topic, we wanted to delve deeper into the key steps to translating MPS from concept to application, identifying the role of different players, showcasing the associated challenges and learning about the future outlook of this technology.
No takes yet. Share an insight, caveat, or question.
A 2026 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: